Skip to content

The efficacy of intrathecal nalbuphine in bilateral total knee arthroplasty

The efficacy of intrathecal nalbuphine in bilateral total knee arthroplasty

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250623002
Enrollment
98
Registered
2025-06-23
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral Total knee arthroplasty Spinal nalbuphine Nalbuphine Intrathecal

Interventions

2.4-3.0 ml (12-15 mg) of 0.5% isobupivacaine +1.5 mg nalbuphine ,2.4-3.0 ml (12-15 mg) of 0.5% isobupivacaine +0.15 ml Normal Saline (NSS)
Experimental Drug,Placebo Comparator No treatment
Intrathecal nalbuphine ,Normal saline

Sponsors

Faculty of Medicine, Siriraj Hospital, Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patient scheduled for elective bilateral total knee arthroplasty under spinal anesthesia 2. American Society of Anesthesiologists(ASA) physical status I-III 3. Age 18-100 years 4. BMI < 40 kg/m2

Exclusion criteria

Exclusion criteria: 1. Patient with contraindication for spinal anesthesia such as patient refusal, infection at the site of injection, increase intracranial pressure or uncorrected hypovolemia. 2. History of allergy or sensitive to drugs used in research: bupivacaine, ketorolac, dexamethasone, paracetamol, tranexamic acid 3. Patient with previous knee surgery 4. Patient with opioid-exposure (defined as any opioid exposure < 60 MED in 90 days prior to DOS) 5. Patient with opioid-tolerance (defined as any opioid exposure >= 60 MED in 7 days prior to DOS) 6. Patient with cognitive impairment who is unable to comprehend or use the verbal rating pain scoring system or patient-controlled analgesia (PCA) pump 7. Patient with chronic kidney disease (CKD) less than eGFR <50 mL/min/1.73m2 8. Patient with Coronary artery disease 9. Patient with cerebrovascular disease

Design outcomes

Primary

MeasureTime frame
efficacy of intrathecal nalbuphine 24 hours postoperatively morphine consumption

Secondary

MeasureTime frame
morphine consumption at 48 and 72 hours postoperatively morphine consumption ,pain intensity at rest and on movement at 0, 4, 8, 12, 24, 48, 72 hours NRS,time to first ambulation - hours,incidence of adverse effects at 72 hours nausea and vomiting, pruritus, respiratory depression and hypotension,satisfaction of patient at 72 hours satisfaction score 1-10

Countries

Thailand

Contacts

Public ContactPeerachatra Mangmeesri

Faculty of Medicine, Siriraj Hospital

peerachatra@hotmail.com0629955659

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026